A novel strategy for NQO1 (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) mediated therapy of bladder cancer based on the pharmacological properties of EO9

The indolequinone EO9 demonstrated good preclinical activity but failed to show clinical efficacy against a range of tumours following intravenous drug administration. A significant factor in EO9's failure in the clinic has been attributed to its rapid pharmacokinetic elimination resulting in p...

Descripción completa

Detalles Bibliográficos
Autores principales: Choudry, G A, Stewart, P A Hamilton, Double, J A, Krul, M R L, Naylor, B, Flannigan, G M, Shah, T K, Brown, J E, Phillips, R M
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2001
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375160/
https://www.ncbi.nlm.nih.gov/pubmed/11710826
http://dx.doi.org/10.1054/bjoc.2001.2056

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375160/
https://www.ncbi.nlm.nih.gov/pubmed/11710826
http://dx.doi.org/10.1054/bjoc.2001.2056

Ejemplares similares